Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma

J Clin Oncol. 2005 Apr 1;23(10):2426-8. doi: 10.1200/JCO.2005.04.079.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / pathology
  • Middle Aged
  • Plasmacytoma / drug therapy*
  • Plasmacytoma / pathology
  • Pyrazines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib